Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A in Buerger's Disease
NCT05698979Phase 3Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2027
- Primary completion
- Feb 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in thromboangiitis obliterans (TAO), sponsored by Centre hospitalier universitaire de Toulouse. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
thromboangiitis obliterans (TAO)
Beyond the preview
Go deeper on NCT05698979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698979.